Source:
Teijin Limited & Cell Therapies Pty Ltd.
“Strategic Business Alliance on Cell and Gene Therapy CDMO in the Asia-Pacific Region” (October 1, 2025)
Official Press Release PDF (Japanese)
🌏 Overview
On October 1, 2025, Teijin Limited (Osaka, Japan; President: Tetsushige Uchikawa) and Cell Therapies Pty Ltd. (Melbourne, Australia; CEO: Bev Menner) announced that they have signed a strategic business alliance agreement to jointly expand cell and gene therapy CDMO services across the Asia-Pacific region, including Japan.
(CDMO = Contract Development and Manufacturing Organization)
This partnership aims to bridge Japan’s advanced regenerative medicine sector with the rapidly growing cell and gene therapy ecosystem throughout the Asia-Pacific market.
🧬 Background: Rising Demand for Cell & Gene Therapy CDMO
The demand for CDMO services in regenerative medicine has been surging, driven by the increasing complexity of product development and the growing trend toward specialized outsourcing.
According to Teijin’s statement, the global CDMO market for regenerative medicine is expected to exceed US $18.6 billion by 2032, while Japan’s domestic market for regenerative products — including overseas entrants — is projected to reach ¥850 billion by 2030.
Teijin emphasizes that connecting domestic and international development pipelines will be crucial to sustaining innovation and industrial growth in the field.
🧫 The Two Partners and Their Strengths
🧪 Teijin Group (Japan)
Teijin operates its regenerative medicine business through subsidiaries including:
- Teijin Regenerative Medicine Inc. (Tokyo), providing advanced R&D and cell-manufacturing platforms.
- Japan Tissue Engineering Co., Ltd. (J-TEC) (Gamagori, Aichi), Japan’s first company to commercialize regenerative medicine products.
Leveraging J-TEC’s clinical experience and Teijin Regenerative Medicine’s technical infrastructure, the group has been developing an integrated CDMO platform that supports clients from early research to commercial production.
🇦🇺 Cell Therapies Pty Ltd. (Australia)
Founded in 2003, Cell Therapies is one of the leading cell and gene therapy CDMOs in the Asia-Pacific.
It holds extensive experience with CAR-T cells, mesenchymal stem cells, and iPS cells, ranging from process development to full-scale GMP manufacturing.
The company has one of the region’s highest numbers of commercial and clinical manufacturing contracts.
🤝 Details of the Alliance
Under this new partnership:
- Infrastructure Collaboration
Teijin Regenerative Medicine and Cell Therapies will jointly develop a cell and gene therapy infrastructure in the Asia-Pacific region, utilizing J-TEC’s technical expertise and regulatory know-how. - Information Sharing & Market Access
Both companies will exchange information on market trends, regulatory frameworks, and clinical trials in Japan and Australia, promoting smoother entry for companies seeking CDMO support in both markets. - Facility & Technology Integration
Each company’s GMP-compliant manufacturing facilities will be mutually utilized, enabling technology transfer and increased manufacturing capacity. - Human Resource Development
Joint training programs and personnel exchanges will help foster the next generation of specialists in cell and gene therapy manufacturing, a skillset in global short supply.
🚀 Future Outlook
Teijin and Cell Therapies plan to build a robust, cross-border manufacturing and development network to accelerate the clinical and commercial adoption of innovative cell and gene therapies across the Asia-Pacific.
Teijin Group has set a sales target of ¥20 billion (approx. US $130 million) in regenerative medicine by 2030, with plans to attract global outsourcing projects, expand facilities, and strengthen workforce training.
This partnership marks a new phase in Japan–Australia collaboration, blending Japan’s precision manufacturing with Australia’s clinical agility to push regenerative medicine forward.
🧭 Commentary
In an era where biotech breakthroughs often depend on scale and speed, this partnership feels like a natural match — Japan’s meticulous craftsmanship meets Australia’s pioneering drive.
Both sides bring what the other needs: regulatory discipline from Tokyo, entrepreneurial energy from Melbourne.
If successful, the Teijin–Cell Therapies alliance could serve as a template for trans-Pacific biotech cooperation — and perhaps even a model for how regenerative medicine businesses expand responsibly in the age of globalization.
📚 References
- Teijin Limited & Cell Therapies Pty Ltd. (2025). Strategic Business Alliance on Cell and Gene Therapy CDMO in the Asia-Pacific Region.
Official PDF (Japanese) News Release Page - Additional context: Japan Tissue Engineering Co., Ltd. (J-TEC); Teijin Regenerative Medicine Inc.
Short quotations and summaries are reproduced for informational and educational purposes with full attribution to Teijin Limited and Cell Therapies Pty Ltd.